Literature DB >> 22859742

A neurobehavioral analysis of the prevention of visual impairment in the DBA/2J mouse model of glaucoma.

Aimée A Wong1, Richard E Brown.   

Abstract

PURPOSE: Timoptic-XE treatment was used to examine the relationship between age-related changes in intraocular pressure (IOP), retinal cell loss, visual ability, and neuronal labeling in the superior colliculus in the DBA/2J mouse model of pigmentary glaucoma.
METHODS: Mice were administered Timoptic-XE (0.0%, 0.25%, or 0.50%) daily from 9 weeks to 12 months of age. Visual ability and IOP were evaluated at 3, 6, 9, and 12 months of age. Mice from each group were then given intraocular injections of wheat germ agglutinin conjugated to horseradish peroxidase (WGA-HRP), and estimates of the number of cells in the ganglion cell layer of the retina, WGA-HRP transneural labeling of cells, cell count, and cross-sectional area of Nissl-stained cells in the superior colliculus were obtained.
RESULTS: Mice treated with 0.50% and 0.25% Timoptic-XE maintained a high level of performance in behavioral vision tasks, while 12-month-old untreated mice (0.0% Timoptic-XE) exhibited impaired visual performance. Timoptic-XE therapy reduced IOP and cell loss in the ganglion cell layer of the retina and prevented somal shrinkage and the decrease in WGA-HRP transneural labeling in the superior colliculus that occurred in untreated mice at 12 months of age.
CONCLUSIONS: This study provides a comprehensive assessment of the efficacy of Timoptic-XE in DBA/2J mice by correlating age-related visual system changes in the retina and brain with changes in IOP and visual ability. These results showed that reducing IOP not only rescued retinal ganglion cell atrophy but also restored visual function and altered patterns of neurodegeneration that occur with blindness.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22859742     DOI: 10.1167/iovs.12-10020

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  19 in total

1.  Early immune responses are independent of RGC dysfunction in glaucoma with complement component C3 being protective.

Authors:  Jeffrey M Harder; Catherine E Braine; Pete A Williams; Xianjun Zhu; Katharine H MacNicoll; Gregory L Sousa; Rebecca A Buchanan; Richard S Smith; Richard T Libby; Gareth R Howell; Simon W M John
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-26       Impact factor: 11.205

Review 2.  Psychophysical testing in rodent models of glaucomatous optic neuropathy.

Authors:  Stephanie L Grillo; Peter Koulen
Journal:  Exp Eye Res       Date:  2015-07-02       Impact factor: 3.467

3.  Combinatorial targeting of early pathways profoundly inhibits neurodegeneration in a mouse model of glaucoma.

Authors:  Gareth R Howell; Katharine H MacNicoll; Catherine E Braine; Ileana Soto; Danilo G Macalinao; Gregory L Sousa; Simon W M John
Journal:  Neurobiol Dis       Date:  2014-08-15       Impact factor: 5.996

Review 4.  Using genetic mouse models to gain insight into glaucoma: Past results and future possibilities.

Authors:  Kimberly A Fernandes; Jeffrey M Harder; Pete A Williams; Rebecca L Rausch; Amy E Kiernan; K Saidas Nair; Michael G Anderson; Simon W M John; Gareth R Howell; Richard T Libby
Journal:  Exp Eye Res       Date:  2015-06-24       Impact factor: 3.467

Review 5.  Development of diagnostic and treatment strategies for glaucoma through understanding and modification of scleral and lamina cribrosa connective tissue.

Authors:  Harry A Quigley; Frances E Cone
Journal:  Cell Tissue Res       Date:  2013-03-28       Impact factor: 5.249

6.  Melanopsin-expressing retinal ganglion cell loss and behavioral analysis in the Thy1-CFP-DBA/2J mouse model of glaucoma.

Authors:  Qi Zhang; Helen Vuong; Xin Huang; YanLing Wang; Nicholas C Brecha; MingLiang Pu; Jie Gao
Journal:  Sci China Life Sci       Date:  2013-06-01       Impact factor: 6.038

Review 7.  Translating ocular biomechanics into clinical practice: current state and future prospects.

Authors:  Michaël J A Girard; William J Dupps; Mani Baskaran; Giuliano Scarcelli; Seok H Yun; Harry A Quigley; Ian A Sigal; Nicholas G Strouthidis
Journal:  Curr Eye Res       Date:  2014-05-15       Impact factor: 2.424

8.  Prevention of vision loss protects against age-related impairment in learning and memory performance in DBA/2J mice.

Authors:  Aimée A Wong; Richard E Brown
Journal:  Front Aging Neurosci       Date:  2013-09-18       Impact factor: 5.750

Review 9.  Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma.

Authors:  Pete A Williams; Jeffrey M Harder; Simon W M John
Journal:  J Glaucoma       Date:  2017-12       Impact factor: 2.503

10.  α-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction.

Authors:  Denise M Inman; Wendi S Lambert; David J Calkins; Philip J Horner
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.